$304.83
+0.14%Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BIO โข NYSE
| Bio-Rad Laboratories, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||||||||||||
CURRENT ASSETS | ||||||||||||||||||||
531.8M | 488.1M | 403.8M | 434.2M | 470.8M | 662.2M | 660.7M | 431.5M | 383.8M | 456.3M | 457.5M | 413.3M | 331.6M | 463.4M | 574.2M | 906.6M | 649.9M | 204.5M | 161.8M | 223.6M | |
1B | 1.2B | 1.2B | 1.4B | 399.1M | 328.9M | 454M | 413.3M | 371.2M | 383.2M | 328.7M | 284.4M | 277.4M | 457.7M | 238.9M | 118.6M | 94.9M | 39M | 62M | 264.5M | |
1.5B | 1.7B | 1.6B | 1.8B | 869.9M | 991.1M | 1.1B | 844.8M | 755M | 839.4M | 786.3M | 697.6M | 608.9M | 921.1M | 813.1M | 1B | 744.8M | 243.5M | 223.7M | 488.1M | |
472.5M | 452.5M | 489M | 494.6M | 423.5M | 419.4M | 392.7M | 392.4M | 464.8M | 372.3M | 391.5M | 377.6M | 422.7M | 398.7M | 398.7M | 388M | 345.7M | 339.7M | 358.1M | 293M | |
460.6M | 452.5M | 489M | 494.6M | 423.5M | 419.4M | 392.7M | 392.4M | 464.8M | 372.3M | 391.5M | 377.6M | 422.7M | 398.7M | 398.7M | 388M | 345.7M | 339.7M | 358.1M | 293M | |
11.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
740.7M | 760M | 780.5M | 719.3M | 572.2M | 622.3M | 554M | 583.8M | 594.8M | 525M | 490.2M | 471M | 516.2M | 455.1M | 433.5M | 398.1M | 351.2M | 375.6M | 321M | 253M | |
136.5M | 122.6M | 140M | 124.2M | 109.1M | 90.6M | 102.3M | 187.2M | 146.1M | 91M | 94.4M | 108.3M | 130.6M | 92.5M | 99.1M | 109.6M | 77.8M | 93.8M | 89.7M | 59.8M | |
13.8M | 30.7M | 31.7M | 29.2M | 15.6M | 16.4M | 16.5M | 15.2M | 15.9M | 16.8M | 15.3M | 61.7M | 79M | 69.3M | 53.8M | 54.4M | 43.1M | 41.4M | 36.5M | 35.9M | |
2.9B | 3B | 3B | 3.2B | 2B | 2.1B | 2.2B | 2B | 2B | 1.8B | 1.8B | 1.7B | 1.8B | 1.9B | 1.8B | 2B | 1.6B | 1.1B | 1B | 1.1B | |
NON-CURRENT ASSETS | ||||||||||||||||||||
709.9M | 688.6M | 723.7M | 679.6M | 716.4M | 693.5M | 701.2M | 508.7M | 493.5M | 488.6M | 437.7M | 428.8M | 414.4M | 416.9M | 349.5M | 333.6M | 302.4M | 300.7M | 271.6M | 189.6M | |
579.8M | 410.5M | 413.6M | 406.5M | 347.3M | 291.9M | 264.1M | 219.8M | 506.1M | 477.1M | 495.9M | 500.4M | 517.8M | 495.4M | 468.9M | 364M | 327.6M | 321.8M | 328.4M | 119.5M | |
174.3M | 293.6M | 320.5M | 332.1M | 253.9M | 199.5M | 145.5M | 133.1M | 174.1M | 161.6M | 214M | 254.2M | 266.2M | 260.9M | 259.5M | 203.9M | 204.8M | 228.6M | 210.3M | 44.6M | |
754.1M | 704.1M | 734.1M | 738.6M | 601.2M | 491.4M | 409.6M | 352.9M | 680.2M | 638.7M | 709.9M | 754.6M | 784M | 756.3M | 728.4M | 567.9M | 532.4M | 550.4M | 538.7M | 164.1M | |
6.1B | 4.8B | 7.7B | 8.8B | 14.4B | 9.6B | 4.6B | 2.7B | 1B | 830.8M | 719.8M | 389.3M | 377.9M | 293.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.5M | 11.2M | 13M | 13.3M | 12.4M | 20.4M | 9.1M | |
102.3M | 101.9M | 94.9M | 94.6M | 104.2M | 86.7M | 79.6M | 70.3M | 94.9M | 47.9M | 64.6M | 52.1M | 55.1M | 24.4M | 209.5M | 173M | 125.1M | 79.8M | 111.9M | 103.6M | |
7.7B | 6.3B | 9.3B | 10.3B | 15.8B | 10.8B | 5.8B | 3.6B | 2.3B | 2B | 1.9B | 1.6B | 1.6B | 1.5B | 1.3B | 1.1B | 973.2M | 943.3M | 942.6M | 466.4M | |
0.0 | 0.0 | 0.0 | 47K | 82K | 13K | 56K | -7K | -18K | 24K | 74K | 69K | -42K | 57K | 30K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
10.6B | 9.4B | 12.3B | 13.5B | 17.8B | 13B | 8B | 5.6B | 4.3B | 3.9B | 3.7B | 3.3B | 3.4B | 3.4B | 3.1B | 3.1B | 2.5B | 2B | 2B | 1.6B | |
LIABILITIES | ||||||||||||||||||||
CURRENT LIABILITIES | ||||||||||||||||||||
165.6M | 153.5M | 180.4M | 167.5M | 188.2M | 196.8M | 143.3M | 178.6M | 175.1M | 161.2M | 29.3M | 163.8M | 182.1M | 165.6M | 181.4M | 164.4M | 135.3M | 151.7M | 124.4M | 83.4M | |
129M | 122.3M | 144.6M | 135M | 141.9M | 139.5M | 107M | 122.5M | 135.2M | 133.1M | 122.4M | 128.6M | 148.5M | 130.9M | 129.1M | 113.4M | 93M | 118M | 96.5M | 83.4M | |
36.6M | 31.2M | 35.8M | 32.4M | 46.3M | 57.3M | 36.3M | 56.2M | 39.9M | 28.1M | -93.1M | 35.2M | 33.6M | 34.8M | 52.3M | 50.9M | 42.3M | 33.7M | 27.9M | 0.0 | |
172.3M | 124.2M | 139.9M | 194.8M | 277M | 222.9M | 180.1M | 143.5M | 171.6M | 163.4M | 280.2M | 153.4M | 160.7M | 165.7M | 137.8M | 23.9M | 46.7M | 30.9M | 44.1M | 132.7M | |
37.9M | 1.2M | 500K | 465K | 489K | 1.3M | 425.7M | 493K | 420K | 334K | 298K | 265K | 1.8M | 1.8M | 814K | 233.2M | 5.1M | 9.6M | 15.6M | 3M | |
0.0 | 41.7M | 40.4M | 36.3M | 36.4M | 37M | 35.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
36.6M | 31.2M | 35.8M | 32.4M | 46.3M | 57.3M | 36.3M | 56.2M | 39.9M | 28.1M | 29.3M | 35.2M | 33.6M | 32.3M | 52.3M | 50.9M | 42.3M | 33.7M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 52.2M | 50.9M | 42.5M | 33.7M | 26.9M | 28.2M | 31M | 29.7M | 26.7M | 26.4M | 26.3M | 24.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
141.2M | 147.2M | 161.6M | 117.4M | 127.9M | 131.1M | 86.8M | 101.2M | 127.3M | 115.4M | 101.8M | 102.6M | 116.6M | 113M | 114.8M | 245.1M | 232.8M | 225.9M | 230.1M | 100.3M | |
517M | 467.8M | 522.8M | 568.7M | 680.9M | 631.5M | 905.5M | 450.8M | 502.7M | 471.3M | 441.4M | 446.8M | 487.5M | 472.4M | 459.1M | 666.6M | 420M | 418M | 414.2M | 319.5M | |
NON-CURRENT LIABILITIES | ||||||||||||||||||||
1.3B | 1.2B | 1.2B | 1.2B | 10.5M | 1.3M | 2.4M | 438.9M | 434.6M | 434.2M | 433.9M | 435.7M | 435.6M | 732.4M | 731.7M | 731.1M | 737.9M | 446M | 441.8M | 425.6M | |
1.1B | 818M | 1.5B | 1.8B | 3.1B | 2.1B | 997.8M | 553.2M | 222.2M | 225.3M | 233.5M | 154.9M | 162.1M | 115.1M | 85.5M | 59.7M | 42.9M | 42.6M | 51.2M | 7.5M | |
53.4M | 177.2M | 195M | 195.9M | 182.2M | 196.9M | 160.9M | 147.8M | 183.3M | 140.5M | 110.5M | 118.7M | 116.9M | 108.1M | 76.1M | 64.8M | 55.9M | 60M | 92.7M | 24M | |
2.6B | 2.3B | 3B | 3.3B | 3.4B | 2.5B | 1.3B | 1.1B | 840.1M | 800M | 777.9M | 709.4M | 714.6M | 955.6M | 893.3M | 855.6M | 836.7M | 548.6M | 585.7M | 457.1M | |
154.4M | 173.1M | 205.9M | 189.9M | 212.4M | 223.1M | 223.1M | 15.7M | 11.9M | 12M | 12.3M | 12.5M | 12.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.1B | 2.8B | 3.6B | 3.9B | 4.1B | 3.1B | 2.3B | 1.6B | 1.3B | 1.3B | 1.2B | 1.2B | 1.2B | 1.4B | 1.4B | 1.5B | 1.3B | 966.6M | 999.9M | 776.6M | |
SHAREHOLDERS' EQUITY | ||||||||||||||||||||
-1B | -772.1M | -632.5M | -263.6M | -106.3M | -99.9M | -38.4M | -49.1M | -217K | -101K | -101K | -101K | -101K | -101K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | |
476M | 463.2M | 449.1M | 447.5M | 441.7M | 429.4M | 410M | 394.3M | 361.2M | 332.9M | 300.4M | 271.3M | 240M | 212.2M | 185.3M | 157M | 130.4M | 124.4M | 98.6M | 78.2M | |
8.2B | 7.4B | 9.3B | 9.9B | 13.5B | 9.3B | 5.5B | 3.7B | 1.8B | 1.8B | 1.8B | 1.7B | 1.6B | 1.5B | 1.4B | 1.2B | 996.2M | 851.6M | 762.1M | 674.1M | |
-189.1M | -538.2M | -336M | -466.8M | -175.6M | 282.5M | -87.3M | -47M | 738.8M | 417.8M | 382.1M | 218.9M | 340.7M | 274.5M | 198.7M | 198M | 133.1M | 65.2M | 111M | 67.2M | |
7.5B | 6.6B | 8.7B | 9.6B | 13.7B | 9.9B | 5.8B | 4B | 2.9B | 2.6B | 2.5B | 2.2B | 2.2B | 2B | 1.7B | 1.5B | 1.3B | 1B | 971.7M | 819.5M | |
7.5B | 6.6B | 8.7B | 9.6B | 13.7B | 9.9B | 5.8B | 4B | 2.9B | 2.6B | 2.5B | 2.2B | 2.2B | 2B | 1.7B | 1.5B | 1.3B | 1.1B | 971.7M | 819.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 535K | 445K | 3.8M | 19.5M | 29.5M | 0.0 | 0.0 | |
SUMMARY | ||||||||||||||||||||
10.6B | 9.4B | 12.3B | 13.5B | 17.8B | 13B | 8B | 5.6B | 4.3B | 3.9B | 3.7B | 3.3B | 3.4B | 3.4B | 3.1B | 3.1B | 2.5B | 2B | 2B | 1.6B | |
7.1B | 6B | 8.9B | 10.2B | 14.8B | 9.9B | 5.1B | 3.1B | 1.4B | 1.2B | 1B | 673.7M | 655.2M | 751.3M | 238.9M | 118.6M | 94.9M | 39M | 62M | 264.5M | |
1.5B | 1.4B | 1.4B | 1.4B | 223.4M | 225.7M | 651.2M | 439.4M | 435M | 434.5M | 434.2M | 436M | 437.4M | 734.2M | 732.5M | 964.3M | 743.1M | 455.6M | 457.4M | 428.7M | |
999.2M | 886.6M | 1B | 953.9M | -247.4M | -436.5M | -9.5M | 7.9M | 51.2M | -21.7M | -23.4M | 22.7M | 105.9M | 270.8M | 158.3M | 57.7M | 93.1M | 251M | 295.7M | 205.1M | |
26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 | 26,974,708 |
BIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 29, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 30, 2025 | September 29, 2025 | 2025 |
Continue your BIO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.